2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Prostatic Neoplasms
9
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Gliosarcoma
4
Glioma
4
Glioblastoma
4
Ganglioneuroblastoma
4
Pancreatic Neoplasms
3
Neuroblastoma
3
Vaginal Neoplasms
2
Thyroid Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma, Ewing
2
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Oligodendroglioma
2
Lung Neoplasms
2
Glioma, Subependymal
2
Ependymoma
2
Cholangiocarcinoma
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Brain Neoplasms
2
Astrocytoma
2
Adenocarcinoma Of Esophagus
2
Wilms Tumor
1
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Thoracic Diseases
1
Interventions
Gemcitabine
95
Cisplatin
72
Capecitabine
39
Oxaliplatin
38
durvalumab
29
Fluorouracil
27
pembrolizumab
26
Leucovorin
23
S 1 (combination)
19
Nivolumab
14
Irinotecan
14
lenvatinib
13
Bevacizumab
13
tremelimumab
10
130-nm albumin-bound paclitaxel
9
apatinib
8
Trastuzumab
7
Injections
7
Immune Checkpoint Inhibitors
7
Docetaxel
7
Albumin-Bound Paclitaxel
7
Paclitaxel
6
Drug Therapy
6
titanium silicide
5
surufatinib
5
irinotecan sucrosofate
5
gemcitabine-oxaliplatin regimen
5
envafolimab
5
camrelizumab
5
atezolizumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
Congresses as Topic
×
Clear all
NCT02784353
2022-11-17
PReHeBP
Asan Medical Center
Phase NA
Completed
158 enrolled